| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.3 | 3e-16 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.29 | 6e-15 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | 0.19 | 1e-07 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | 0.19 | 4e-07 |
| mRNA | Ki8751 | CTRPv2 | pan-cancer | AAC | 0.19 | 7e-07 |
| mRNA | tretinoin:carboplatin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.18 | 8e-07 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.27 | 1e-06 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.18 | 3e-06 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.18 | 3e-06 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.17 | 4e-06 |